Bayer has approached US drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.
The two companies are working with banks to ensure any merger would secure regulatory approval, the sources said, speaking on condition of anonymity.
Bayer has delayed the launch of an auction to private equity funds to clinch a bilateral deal with Elanco, the fourth-largest player in the animal health industry globally, the sources said.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ABC Technologies Offers to Acquire TI Fluid for £1.83 Billion
Dec 1, 2024 by
CPI
Concerns Mount as Mexico Moves Forward with Telecom Regulator Overhaul
Dec 1, 2024 by
CPI
States Challenge ‘Green Agenda’: Major Asset Managers Accused of Antitrust Breach
Dec 1, 2024 by
CPI
Google Seeks Reversal of Antitrust Ruling in Epic Games Case
Dec 1, 2024 by
CPI
Meta Accused of EU Data Violations in €551 Million Spanish Lawsuit
Dec 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead